Exchange: NASDAQ·Updated 07:30 PM EDT

ATRC News

News
all
press releases
AtriCure CTO Sells 3,657 Shares
Key PointsThe transaction was valued at $201,000...
Nasdaq News: Markets
More News
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Zacks
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care...
Business Wire
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Key PointsThis disposition involved 3,500 shares at $38.42 per share, totaling $134,470...
Nasdaq News: Markets
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Key PointsKaren Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5...
Nasdaq News: Markets
Director At AtriCure Sells $134K Of Stock
It was reported on August 7, that Maggie Yuen, Director at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities andread more...
Benzinga
Are Options Traders Betting on a Big Move in AtriCure Stock?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCures...
Business Wire

Advertisement|Remove ads.